Documented cause
54gene was founded in 2019 in Lagos, Nigeria by Abasi Ene-Obong, a Nigerian physician with a PhD from Harvard. The company's thesis was both scientifically compelling and commercially underexplored: over 96% of genomic research globally uses subjects of European ancestry, making the resulting genetic databases essentially useless for understanding disease risk and drug efficacy in African populations. 54gene aimed to build the largest repository of African human genomic data, partnering with Nigerian teaching hospitals to sequence patients and license this data to pharmaceutical companies for drug discovery. The company raised $45 million from Adjuvant Capital, AXA IM Alts, Owl Ventures, and the Open Society Foundations, and was a Y Combinator W2019 alumnus. But the path to revenue in genomics is measured in years, not months: pharmaceutical drug discovery partnerships operate on multi-year timelines, regulatory approval for biospecimen collection in Nigeria was complex, and the company needed to build lab infrastructure while simultaneously creating the commercial pipeline. In February 2023, Abasi Ene-Obong announced that 54gene was shutting down. In a widely shared statement he wrote: "The funding environment has made it impossible for us to continue." The scientific case remained correct; the capital did not outlast the timeline.
Alternative account: 54gene raised $45M from Y Combinator, Craft Ventures, and others to address a critical problem in global healthcare: most genomic research is conducted on European and North American populations, leaving African genetic variants poorly understood. The company aimed to build Africa-specific biobanks and sell data to pharmaceutical partners. The biobank business model requires long sales cycles to pharma partners and high collection infrastructure costs. Unable to raise additional capital in the 2023 biotech funding drought, 54gene shut down in November 2023.